MO18-4 RAS status in ctDNA and efficacy of FOLFIRI plus ramucirumab in 2nd-line therapy for RAS wild-type mCRC: JACCRO CC-16AR

RAS status in circulating-tumor DNA (ctDNA) is considered to be associated with resistance and potential efficacy of re-challenge treatment of anti-EGFR antibody in RAS wild-type metastatic colorectal cancer (mCRC). However, there were few evidence to evaluate the association between RAS status in ctDNA and clinical outcomes of combination chemotherapy with anti-angiogenic drug after anti-EGFR therapy for mCRC.